← All Signals

🏥 FDA: F.H. INVESTMENTS, Inc. (dba Asteria Health) — Class II

healthcarebearishSource: FDA
95%Confidence
0Views
FDASource
2026-03-06Date

Summary

Third testosterone recall for Asteria Health confirms widespread contamination issues across their product line. This could lead to complete market withdrawal and significant regulatory penalties for the company.

Actionable: Seek alternative testosterone pellet suppliers and monitor for potential company closure.

AI Confidence: 95%

Data Points

firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 25.0 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1025-32.

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now